Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: InterVentional Technologies

This article was originally published in The Gray Sheet

Executive Summary

InterVentional Technologies: Firm's TOPIT (TEC or PTCA in Thrombus) study is halted following an interim analysis of results from 250 patients. The study, intended to include 550 patients, was comparing the frequency of "major in-hospital complications" in acute ischemic syndrome patients treated with extraction atherectomy using IVT's TEC device to patients treated via conventional percutaneous transluminal angioplasty. According to IVT, the study's primary investigator William O'Neill, MD, concluded that the trial should be stopped because "patient safety was very significantly compromised in the treatment arm that excluded the use of TEC." Data from TOPIT are scheduled to be presented Nov. 12 at the American Heart Association scientific sessions in New Orleans...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel